Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Adams et al. (Thu,) studied this question.

www.synapsesocial.com/papers/69d8d15017a1cc0598d18a0d — DOI: https://doi.org/10.1093/annonc/mdy517

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer· 2010 · 4,245 citations
2. Time for more optimism in metastatic breast cancer?· 2013 · 69 citations
3. The blockade of immune checkpoints in cancer immunotherapy· 2012 · 13,660 citations
4. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients· 2013 · 227 citations
5. Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086· 2017 · 185 citations